Antifibrotic drug discovery / edited by Jehrod Brenneman, KSQ Therapeutics, USA and Malliga R. Iyer, National Institutes of Health, USA

Mitwirkende(r):

Resource type: Ressourcentyp: Buch (Online)Buch (Online)Sprache: Englisch Reihen: RSC drug discovery series ; 73Verlag: London : Royal Society of Chemistry, 2020Copyright-Datum: © 2020Beschreibung: 1 Online-Ressource (xvi, 347 Seiten)ISBN:

9781788015783
9781839160516

Schlagwörter:

Andere physische Formen: 9781788015103 | Erscheint auch als: Anti-fibrotic drug discovery Druck-Ausgabe.DDC-Klassifikation:

615.19

LOC-Klassifikation:

RM301.25

DOI: DOI: 10.1039/9781788015783Online-Ressourcen:

Zugang im Netz des KIT

Zusammenfassung: TGFß Signalling in Fibrosis; Targeting Integrins in Fibroproliferative Disease; Discovery, Structural Refinement and Therapeutic Potential of Farnesoid X Receptor (FXR) Activators; Autotaxin Inhibitors in Fibrosis; Inhibition of LOXL2 and Other Lysyl Oxidase (Like) Enzymes: Intervention at the Core of Fibrotic Pathology; Galectin-3 Involvement in Fibrotic Diseases; The Emerging Role of CXCR4 in IPF; BH3 Mimetic Drugs for Anti-Fibrotic Therapy; Intratumoral Fibrosis: Emerging Concepts and Therapeutic Opportunities; Targeting Fibroblasts in Cancer and FibrosisZusammenfassung: Anti-fibrotic Drug Discovery is ideal for postgraduate students and researchers with an interest in anti-fibrotic drug discovery as well as clinicians specialising in liver, kidney, heart and lung disease, in which fibrosis plays a key role in pathologyPPN: PPN: 1690289961Package identifier: Produktsigel: ZDB-1-RSEK

Exemplare ( 0 )

Dieser Titel hat keine Exemplare

Anti­fibrotic drug discovery / edited by Jehrod Brenneman, KSQ ­Therapeutics, USA and Malliga R. Iyer, National Institutes of Health, USA

Antifibrotic drug discovery / edited by Jehrod Brenneman, KSQ Therapeutics, USA and Malliga R. Iyer, National Institutes of Health, USA